GSK joins pharma giants dropping anti-TIGIT drugs. The news may come as a shock to the oncology field, as GSK and iTeos provided the first data for the GALAXIES Lung-201 study at the European ...

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

GSK said that the EOS-448/Jemperli combination will start a large randomised trial next year, adding that it now has drug candidates addressing "all three known CD226 checkpoints – TIGIT, CD96 ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

When added to GSK’s drug Jemperli, the immunotherapy, known as belrestotug and aimed at a cellular target called TIGIT, didn’t meet preset criteria for progression-free survival compared to ...

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target. Results come amid broader doubts about the approach among some. Manage alerts for this article; ...

iTeos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am rating RCUS stock a Hold for now.

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...